Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885436 | 1.00 | NR1H2 (0.40) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL13765261 | 0.85 | NR1H2 (0.40) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL31239021 | 0.79 | MAPK1 (0.37) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL30636995 | 0.76 | NR1H2 (0.49) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL32664237 | 0.76 | CHRM2 (0.38) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL1178044 | 0.74 | NR1H2 (0.41) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL1178045 | 0.74 | NR1H2 (0.41) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL1178043 | 0.74 | NR1H2 (0.41) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL12870257 | 0.74 | NR1H2 (0.41) | NR1H2MEN1KMT2ACHRM2CHRM1 | |
| SCHEMBL28839780 | 0.74 | NR1H2 (0.38) | NR1H2MEN1KMT2ACHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, NSUN3, POLR2H | NR1H2 649/4885MEN1 3549/4885KMT2A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.